Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSPE.L Regulatory News (SPE)

  • There is currently no data for SPE

Accolade Release 10.2

21 Jan 2016 08:29

RNS Number : 5678M
Sopheon PLC
21 January 2016
 

SOPHEON PLC

("Sopheon" or the "Company")

 

Accolade Release 10.2 Increases Innovation Project Velocity

 

Sopheon, the international provider of software, expertise, and best practices for Enterprise Innovation Performance, announces today the latest version of its Accolade Enterprise Innovation Management solution.

Accelerated innovation velocity: Time is money, and creating new technologies and bringing new products to market more quickly means increased profits and revenues. Intelligent automation and smart workflows in Accolade 10.2 reduce the amount of manual intervention required for innovation processes to keep moving forward at pace, and enhance the flow of communication and collaboration across even highly dispersed work teams. Companies can use these capabilities to accelerate project velocity and time to market, helping them move with greater speed and focus towards the next innovation milestone.

A Sopheon customer-a multi-billion dollar chemical company and early reviewer of Accolade release 10.2-plans to significantly reduce time-lags and human error in the decision-making process by having their Accolade system automatically move projects to the next stage in the development cycle. These migrations will be triggered when pre-defined key performance indicators are met and/or when all relevant stakeholders have given approval in Accolade.

More focused and efficient user experience: This release is another step forward in raising the industry standard on user engagement in the innovation process by bringing critical documents, information and data into core innovation workflows, enabling people to complete their work more efficiently and with less effort.

Don Sarno, Chief Operating Officer at Sopheon says, "CEOs understand that speed-to-market and agility are competencies critical to surviving in the new norm of competitive markets. With Accolade release 10.2, we continue to provide a tight alignment and personal connection between team member activities and company value, in addition to reducing wasted cycles from the top of the organization to the front line."

 

Sopheon® and Accolade® are trademarks of Sopheon.

 

 

For further information contact:

Barry Mence, Chairman

Sopheon plc

+ 44 (0) 1276 919 560

Arif Karimjee, CFO

Sopheon plc

+ 44 (0) 1276 919 560

Ed Frisby / Carl Holmes (corporate finance)

Mia Gardener (corporate broking)

finnCap

+ 44 (0) 20 7220 0500

 

 

About Sopheon. Sopheon (LSE: SPE) partners with customers to provide complete enterprise innovation management solutions including software, expertise, and best practices, that enable them to achieve exceptional long-term revenue growth and profitability. Sopheon's Accolade solution provides unique, fully-integrated coverage for the entire innovation management and new product development lifecycle, including strategic innovation planning, roadmapping, idea and concept development, process and project management, portfolio management and resource planning. Sopheon's solutions have been implemented by over 200 customers with over 60,000 users in over 50 countries. Sopheon is listed on AIM, operated by the London Stock Exchange. For more information, please visit www.sopheon.com.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAAKDDBFBKKFDB
Date   Source Headline
27th Jan 20117:00 amPRNTrading Statement
9th Dec 20107:00 amPRNAmendment to the Terms of Convertible Loan Stock
16th Nov 20107:00 amPRNContract Win
4th Nov 20107:00 amPRNInterim Management Statement
27th Aug 201010:30 amPRNGrant of Options
26th Aug 20107:00 amPRNHalf-yearly Report
22nd Jul 20107:00 amRNSTrading Update
15th Jun 20105:31 pmPRNResult of AGM
15th Jun 20107:00 amPRNAGM Statement
18th May 20107:00 amRNSAfton Chemical Selects Idea Lab
6th May 20107:00 amPRNInterim Management Statement
25th Mar 20107:00 amPRNFinal Results
22nd Mar 20107:00 amRNSiSUSTAINT Alliance Launched
3rd Feb 20107:00 amRNSSopheon Team wins TARDEC Contract
28th Jan 20107:00 amPRNTrading Update
24th Dec 20097:01 amRNSExtension of GEM Equity Line
2nd Dec 20097:00 amRNSVision Strategist Version 5.0 Launched
3rd Nov 20097:00 amPRNInterim Management Statement
2nd Oct 20093:43 pmPRNISSUE OF CONVERTIBLE LOAN STOCK
27th Aug 20097:00 amPRNHalf-yearly Report
16th Jun 200912:34 pmPRNResult of AGM
16th Jun 20097:00 amPRNAGM Statement
19th May 20097:00 amPRNProduct Launch
7th May 20097:00 amPRNInterim Management Statement
26th Mar 20097:00 amPRNFinal Results
18th Mar 20097:00 amRNSBostik Implements Sopheon's Accolade System
11th Mar 20097:00 amRNSContract Win
11th Feb 20097:00 amRNSEnhanced Version of Accolade? Launched
28th Jan 20097:00 amPRNTrading Update
21st Jan 20097:00 amRNSSopheon Partners with Maxsoft
4th Nov 20087:00 amPRNInterim Management Statement
28th Aug 20087:00 amPRNHalf-yearly Report
27th Jun 20083:47 pmPRNDirector/PDMR Shareholding
25th Jun 20087:00 amPRNGrowth Milestone
10th Jun 20087:00 amPRNAGM Statement
16th May 20087:00 amPRNDirector/PDMR Shareholding
15th May 20087:00 amPRNInterim Management Statement
6th May 200810:00 amPRNNotice of AGM
29th Apr 20087:02 amRNSContract Win
1st Apr 200810:00 amPRNGrant of Options
27th Mar 20087:00 amPRNFinal Results
6th Feb 20087:01 amRNSProduct Development
25th Jan 20087:00 amPRNTrading Update
21st Dec 200710:30 amPRNTrading Update
25th Oct 20077:00 amPRNTrading Update
16th Oct 20072:38 pmBUSBeiersdorf Implements Sopheon System in Support of Product Innovation Strategy
16th Oct 20077:01 amRNSContract Win
10th Oct 20072:45 pmBUSLeading European Center for Clinical Trials Research Selects Sopheon's Accolade(R) System
10th Oct 20077:01 amRNSContract Win
1st Oct 20077:02 amRNSContract Win

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.